SGP

SpyGlass Pharma, Inc. Common Stock

Nasdaq · usd

$30.07+1.59 (+5.59%)

As of 2:05:14 PM EDT on Oct 26, 2026 · 15-minute delayed

SpyGlass Pharma, Inc. Common Stock (SGP) trades at $30.07 (+5.59%) as of 2:05:14 PM EDT on Oct 26, 2026, +10.82% over the past month. Market cap is $952.6M, with 7.1 days to cover in short interest.

Stock performance

How SpyGlass Pharma, Inc. Common Stock (SGP) stock has performed from one day to one year, with its 52-week range.

+6.91%

+$1.94 over 1D

1D: +5.34%
1W: +21.95%
1M: +10.82%
YTD: +13.64%
1Y: +13.64%
52-wk range: $17.06 – $32.44

Key statistics

Today's trading snapshot for SGP: day range, open, previous close, volume and market cap.

Day range: $28.09 – $30.11
Open: $29.21
Prev close: $28.48
Volume: 38.83K
Market cap: $952.6M
Shares out: 33.45M

Insider buying and selling

In the 12 months to Oct 26, 2026, 15 SGP insiders reported open-market purchases of $221.5M across 16 filings; no open-market sales were filed.

Who traded SGP, and when

Purchase

SGP daily closelast $30.00

Rajeev M. Shah · Director

$55.1M bought

Ali Behbahani · Director

$15.0M bought

Anthony A. Florence JR. · 10% owner

$15.0M bought

Carmen Chang · 10% owner

$15.0M bought

Edward T. Mathers · 10% owner

$15.0M bought

Forest Baskett · 10% owner

$15.0M bought

Mohamad Makhzoumi · 10% owner

$15.0M bought

NEA Partners 17, L.P. · 10% owner

$15.0M bought

Paul Edward Walker · 10% owner

$15.0M bought

Rick Yang · 10% owner

$15.0M bought

Scott D. Sandell · 10% owner

$15.0M bought

Kirk G. Nielsen · Director → 10% owner

$5.3M bought

Geoffrey B. Pardo · Director

$5.0M bought

Peter Kolchinsky · Director

$4.0M bought

Bilal Arshad Khan · Director

$2.2M bought

One row per insider; marks sit at the SEC filing date, sized by dollar value.

See who traded and when →

8-K filings

Material corporate events SpyGlass Pharma, Inc. Common Stock has disclosed to the SEC on Form 8-K.

Clinical trial resultsOct 19, 2026
On October 19, 2026, SpyGlass Pharma, Inc. issued a press release providing positive interim 4-year data from its first-in-human trial of its Bimatoprost Drug Pad-IOL System.
Acquisition completionOct 1, 2026
At the closing under the Purchase Agreement, which occurred on October 1, 2026 (the "Closing"), the Company acquired 100% of the outstanding equity securities (the "Shares") of Advanced Vision Science, Inc., a California corporation ("AVS"), from Seller (the "Acquisition"). The aggregate consideration paid by the Company at the Closing for the Shares was based on a purchase price of $13,000,000, subject to customary adjustments.
Clinical trial resultsMar 9, 2026
SpyGlass Pharma, Inc. issued a press release providing positive top-line 12-month clinical updates on its innovative Bimatoprost Drug Pad-IOL System Phase 1/2 trial.
Executive compensation changeFeb 13, 2026
On February 12, 2026, the Compensation Committee approved performance cash bonuses earned by the Named Executive Officers for Fiscal Year 2025, which will be paid shortly following such approval. In accordance with Item 5.02(f) of Form 8-K, set forth below is an updated 'Summary Compensation Table for Fiscal 2024 and 2025', which includes the amount of performance cash bonuses earned by the Named Executive Officers for Fiscal Year 2025 in the 'Non-Equity Incentive Plan Compensation' column.
Director appointmentFeb 9, 2026
Habib Dable was appointed to the board of directors of SpyGlass Pharma, Inc. (the "Company") on February 5, 2026 in connection with the Company's initial public offering (the "IPO"). Mr. Dable will serve as a Class I director until a successor is duly elected and qualified or until an earlier resignation or removal. Mr. Dable will serve as a member of the compensation committee of the board of directors of the Company.

Dividend history and stock splits

SpyGlass Pharma, Inc. Common Stock's recent dividend payments and stock splits.

Dividends

$0.07ex-div Oct 22, 2009
$0.07ex-div Aug 5, 2009
$0.07ex-div Apr 29, 2009
$0.07ex-div Feb 4, 2009

Splits

No recent splits.

SGP short interest

How heavily SGP is shorted: shares short, days to cover and average daily volume.

Days to cover: 7.1
Short interest: 1.25M
Avg volume: 176.36K

As of Sep 30, 2026 · reported to FINRA twice monthly.

SGP news

The latest news and headlines about SpyGlass Pharma, Inc. Common Stock (SGP).

SpyGlass Pharma Appoints Shannon Treviño as General Counsel
positiveGlobeNewswire Inc.· Jun 15, 2026

Frequently asked questions

What is the SpyGlass Pharma, Inc. Common Stock (SGP) stock price today?

SpyGlass Pharma, Inc. Common Stock (SGP) is trading at $30.07 (+5.59% on the day) as of 2:05:14 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is SpyGlass Pharma, Inc. Common Stock?

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines.

What is the short interest in SGP?

As of Sep 30, 2026, SGP has 1.25M shares short and 7.1 days to cover.

Does SpyGlass Pharma, Inc. Common Stock (SGP) pay a dividend?

Yes. SpyGlass Pharma, Inc. Common Stock (SGP)'s most recent dividend was $0.07 per share, with an ex-dividend date of Oct 22, 2009. Full SGP dividend history is available from the Massive API.

What exchange is SGP listed on?

SpyGlass Pharma, Inc. Common Stock (SGP) trades on Nasdaq in USD, in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry.

Build with AI

Build an analysis of SGP with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Claude ChatGPT

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a SGP analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.